Biosketch Marcos Malumbres

Marcos Malumbres
mmalumbres@vhio.net
LinkedIn: https://www.linkedin.com/in/marcos-malumbres/
Twitter: @MalumbresLab
Google Scholar: https://scholar.google.com/citations?hl=en&user=PuGGz7EAAAAJ
Lab webpage: https://malumbreslab.org/
Position
  • Group Leader, Cancer Cell Cycle group
  • ICREA Professor
Honors and Memberships
  • EMBO member
  • Scientific Advisory Board, European TRANSCAN (http://transcan.eu/)
  • Molecular Tumour Board, SOLTI-HOPE
  • Scientific Advisory Board, Worldwide Cancer Research (WCR)
  • Board of Trustees, Spanish Association against Cancer (AECC)
  • Scientific Advisory Board of the Institute of Molecular Genetics Academy of Sciences of the Czech Republic.
  • Visiting Professor, Dana Farber Cancer Institute, Harvard University, Boston
Academic Qualifications
  • 2023-present. Senior Group Leader at Vall d’Hebron Institute of Oncology (VHIO).
  • 2023-present. External Affiliated Faculty at the Institute for Research in Biomedicine (IRB Barcelona).
  • 2023-present. ICREA Professor
  • 2005-2022. Senior Group Leader at Spanish National Cancer Research Centre (CNIO), Madrid.
  • 2004. Staff Position at Spanish National Research Council (CSIC). (On-leave-)
  • 1999-2004. Senior Group Leader at Spanish National Cancer Research Centre (CNIO), Madrid. PI: Mariano Barbacid
  • 1998-1999. Senior Group Leader at Spanish National Cancer Research Centre (CNIO), Madrid. PI: Mariano Barbacid
  • 1994-1998. Postdoctoral Fellow at New York University Medical Center (NY, USA). PI: Angel Pellicer
  • 1988-1993. PhD in Molecular Biology by the Universidad de León PI: Juan Francisco Martín
  • 1987. Degree in Biological Sciences by the Universidad de Navarra, Pamplona.
ICREA Professor
  • Mechanisms of resistance to CDK4/6 inhibitors: biomarkers and combinatorial therapies
  • Novel therapeutic approaches based on unconventional CDKs
  • Combination between core cell cycle- and DNA damage-targeted therapies
  • Self-renewal of pluripotent cells and regeneration
Publications

Villarroya-Beltri C, Martins AFB, García A, Giménez D, Zarzuela E, Novo M, Del Álamo C, González-Martínez J, Bonel-Pérez GC, Díaz I, Guillamot M, Chiesa M, Losada A, Graña-Castro O, Rovira M, Muñoz J, Salazar-Roa M, Malumbres M. (2023) Mammalian CDC14 phosphatases control exit from stemness in pluripotent cells. EMBO J42, e111251. doi: 10.15252/embj.2022111251. [PMID: 36326833]

Sanz-Castillo B, Hurtado B, Vara-Ciruelos D, El Bakkali A, Hermida D, Salvador-Barbero B, Martínez-Alonso D, González-Martínez J, Santiveri C, Campos-Olivas R, Ximénez-Embún P, Muñoz J, Álvarez-Fernández M, Malumbres M. (2023) The MASTL/PP2A cell cycle kinase-phosphatase module restrains PI3K-Akt activity in an mTORC1-dependent manner. EMBO J. 42, e110833. doi: 10.15252/embj.2022110833. [PMID: 36354735]

Olivera-Salguero R, Seguí E, Cejalvo JM, Oliveira M, Tolosa P, Vidal M, Malumbres M, Gavilá J, Saura C, Pernas S, López R, Margelí M, Balmaña J, Muñoz M, Blancas I, Boni V, Ciruelos E, Galve E, Perelló A, Sánchez-Bayona R, de la Cruz S, de la Hoya M, Galván P, Sanfeliu E, Gonzalez-Farre B, Sirenko V, Blanch-Torras A, Canes J, Masanas H, Olmos R, Forns M, Prat A, Casas A*, Pascual T* (2023) HOPE (SOLTI-1903) Breast Cancer Study: Real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer. Front Oncol 13:1151496. [PMID: 37188177]

Martínez-Illescas NG, Leal S, González P, Graña-Castro O, Muñoz-Oliveira JJ, Cortés-Peña A, Gómez-Gil M, Vega Z, Neva V, Romero A, Quintela-Fandino M, Ciruelos E, Sanz C, Aragón S, Sotolongo L, Jiménez S, Caleiras E, Mulero F, Sánchez C*, Malumbres M*, Salazar-Roa M*. (2023) miR-203 drives breast cancer cell differentiation. Breast Cancer Res 25:91. doi: 10.1186/s13058-023-01690-9. [PMID: 37542268]

Frontiñán-Rubio J, Llanos-González E, García-Carpintero S, Peinado JR, Ballesteros-Yáñez I, Rayo MV, de la Fuente J, Pérez-García VM, Perez-Romasanta LA, Malumbres M, Alcaín FJ, Durán-Prado M. (2023) CoQ10 reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation. Cell Oncol 46, 65-77. doi: 10.1007/s13402-022-00734-0. [PMID: 36319818]

Dhital B, Santasusagna S, Kirthika P, Xu M, Li P, Carceles-Cordon M, Soni RK, Li Z, Hendrickson RC, Schiewer MJ, Kelly WK, Sternberg CN, Luo J, Lujambio A, Cordon-Cardo C, Alvarez-Fernandez M, Malumbres M, Huang H, Ertel A, Domingo-Domenech J, Rodriguez-Bravo V. (2023) Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. Cell Rep Med. 4, 100937. doi: 10.1016/j.xcrm.2023.100937. [PMID: 36787737]

Mouron S, Bueno MJ, Muñoz M, Torres R, Rodríguez S, Apala JV, Silva J, Sánchez-Bayona R, Manso L, Guerra J, Rodriguez-Lajusticia L, Malon D, Malumbres M, Quintela-Fandino M. (2023) p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancer. JNCI Cancer Spectr. Feb 20:pkad014. doi: 10.1093/jncics/pkad014. [PMID: 36806942]

Sayago C, Sánchez-Wandelmer J, García F, Hurtado B, Lafarga V, Prieto P, Zarzuela E, Ximénez-Embún P, Ortega S, Megías D, Fernández-Capetillo O, Malumbres M, Munoz J. (2023) Decoding protein methylation function with thermal stability analysis. Nat Commun. 14, 3016. [PMID: 37230995] doi: 10.1038/s41467-023-38863-1.

Baldrighi, M., Doreth, C., Li, Y., Zhao, X., Warner, E., Chenoweth, H., Kishore, K., Umrania, Y., Minde, D.P., Thome, S., Yu, X., Lu, Y., Knapton, A., Harrison, J., Clarke, M., Latz, E., de Carcer, G., Malumbres, M., Ryffel, B., Bryant, C., Liu, J., Lilley, K.S., Mallat, Z., Li, X. (2023) PLK1 inhibition dampens NLRP3 inflammasome-elicited response in inflammatory disease models. J Clin Invest 133, e162129. [PMID: 37698938]

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer. Olivera-Salguero R, Seguí E, Cejalvo JM, Oliveira M, Tolosa P, Vidal M, Malumbres M, Gavilá J, Saura C, Pernas S, López R, Margelí M, Balmaña J, Muñoz M, Blancas I, Boni V, Ciruelos E, Galve E, Perelló A, Sánchez-Bayona R, de la Cruz S, de la Hoya M, Galván P, Sanfeliu E, Gonzalez-Farre B, Sirenko V, Blanch-Torras A, Canes J, Masanas H, Olmos R, Forns M, Prat A, Casas A, Pascual T. Front Oncol. 2023 Apr 28;13:1151496. doi: 10.3389/fonc.2023.1151496. eCollection 2023.https://pubmed.ncbi.nlm.nih.gov/37188177/

Decoding protein methylation function with thermal stability analysis.Sayago C, Sánchez-Wandelmer J, García F, Hurtado B, Lafarga V, Prieto P, Zarzuela E, Ximénez-Embún P, Ortega S, Megías D, Fernández-Capetillo O, Malumbres M, Munoz J. Nat Commun. 2023 May 25;14(1):3016. doi: 10.1038/s41467-023-38863-1.https://pubmed.ncbi.nlm.nih.gov/37230995/

Projects

A new platform to predict response to CDK4/6 inhibitors in metastatic breast cancer patients

Reference: DTS21/00132
Ministerio de Ciencia e Innovación
Award Period: 01/2022-12/2023.
PI: Marcos Malumbres

Therapeutic evaluation of the Cdk14-18 subfamily in advanced breast cancer (breastCDKS)

Reference: PID2021-128726OB-I00
Ministerio de Ciencia e Innovación
Award Period: 1/2022-31/2024
IP: Marcos Malumbres

Implementing CDK16-18 targeted therapies for cancer treatment

PDC2022-133408-I00
Ministerio de Ciencia e Innovación
Award Period: 1/2023-31/2024
IP: Marcos Malumbres

Balance entre Proliferación y diferenciación: Mecanismos y Relevancia en Patología Humana

Entidad Financiadora: MCIN/AEI/10.13039/501100011033
Ref: RED2022-134792-T
Periodo de Ejecución: 01/06/2023 – 31/05/2025
Coordinador: Marcos Malumbres
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.